Henry Schein authorizes repurchase of up to $750M in stock
By HME News Staff
Updated 12:11 PM CDT, Wed September 10, 2025
MELVILLE, N.Y. – Henry Schein’s board of directors has authorized the repurchase of up to $750 million of shares of the company's common stock. This program is in addition to the $500 million repurchase program announced in January 2025, which is anticipated to be fully executed by the end of the first quarter of 2026. Henry Schein had approximately 118.6 million shares outstanding as of Sept. 8, 2025. This new authorization represents approximately 9% of shares outstanding at the current stock price. Purchases may be made from time to time in the open market, or through negotiated transactions. “Henry Schein’s decision to repurchase shares reflects the confidence we have in our 2025–27 BOLD+1 Strategic Plan and its potential to deliver sustainable growth and value,” said Ronald N. South, senior vice president and CFO. “With the support of a strong balance sheet, we are well positioned to serve our markets and further expand the depth and reach of our health care solutions.”
Comments